VivoSeq
Cardiovascular

Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)

1

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome) is an early-stage landscape with 1 program across 2 companies. The most active players are Tisento Therapeutics, Eli Lilly.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

Tisento Therapeutics

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

Zagociguat

Tisento Therapeutics

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

2

clinical trials

Completed1 · 50%
Active, not recruiting1 · 50%

Clinical Trials

Trial Activity

Phase 2b Randomized, Double-blind, Placebo-controlled Crossover Study Evaluating the Efficacy and Safety of Zagociguat in Participants With MELAS (PRIZM)
Completed·TTisento Therapeutics·Phase 2·NCT06402123·43 enrolled
An Open-label Extension Study Evaluating the Safety of Zagociguat in Participants With MELAS Who Completed TIS6463-203
Active, not recruiting·TTisento Therapeutics·Phase 2·NCT06961344·44 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)